Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Christoph Dehnhardt"'
Autor:
JP Johnson, Thilo Focken, Kuldip Khakh, Parisa Karimi Tari, Celine Dube, Samuel J Goodchild, Jean-Christophe Andrez, Girish Bankar, David Bogucki, Kristen Burford, Elaine Chang, Sultan Chowdhury, Richard Dean, Gina de Boer, Shannon Decker, Christoph Dehnhardt, Mandy Feng, Wei Gong, Michael Grimwood, Abid Hasan, Angela Hussainkhel, Qi Jia, Stephanie Lee, Jenny Li, Sophia Lin, Andrea Lindgren, Verner Lofstrand, Janette Mezeyova, Rostam Namdari, Karen Nelkenbrecher, Noah Gregory Shuart, Luis Sojo, Shaoyi Sun, Matthew Taron, Matthew Waldbrook, Diana Weeratunge, Steven Wesolowski, Aaron Williams, Michael Wilson, Zhiwei Xie, Rhena Yoo, Clint Young, Alla Zenova, Wei Zhang, Alison J Cutts, Robin P Sherrington, Simon N Pimstone, Raymond Winquist, Charles J Cohen, James R Empfield
Publikováno v:
eLife, Vol 11 (2022)
NBI-921352 (formerly XEN901) is a novel sodium channel inhibitor designed to specifically target NaV1.6 channels. Such a molecule provides a precision-medicine approach to target SCN8A-related epilepsy syndromes (SCN8A-RES), where gain-of-function (G
Externí odkaz:
https://doaj.org/article/ff1c4ccf767e411f85c1b12a0db8fe55
Autor:
Jay Gibbons, Semiramis Ayral-Kaloustian, Osvaldo dos Santos, Zecheng Chen, Efren Delos Santos, Christoph Dehnhardt, Aranapakam Venkatesan, Veronica Soloveva, Judy Lucas, Larry Feldberg, Irwin Hollander, Robert Mallon
Adobe PDF - Supplementary_Data.pdf from Antitumor Efficacy Profile of PKI-402, a Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::709b28e2f7bf6d37c791b4af89125c81
https://doi.org/10.1158/1535-7163.22485176
https://doi.org/10.1158/1535-7163.22485176
Autor:
Jay Gibbons, Semiramis Ayral-Kaloustian, Osvaldo dos Santos, Zecheng Chen, Efren Delos Santos, Christoph Dehnhardt, Aranapakam Venkatesan, Veronica Soloveva, Judy Lucas, Larry Feldberg, Irwin Hollander, Robert Mallon
PKI-402 is a selective, reversible, ATP-competitive, equipotent inhibitor of class I phosphatidylinositol 3-kinases (PI3K), including PI3K-α mutants, and mammalian target of rapamycin (mTOR; IC50 versus PI3K-α = 2 nmol/L). PKI-402 inhibited growth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d8f1cc874f1a18d6a1152eb720ccdae
https://doi.org/10.1158/1535-7163.c.6531812
https://doi.org/10.1158/1535-7163.c.6531812
Autor:
Irwin Hollander, Aranapakam Venkatesan, Semiramis Ayral-Kaloustian, Osvaldo dos Santos, Zecheng Chen, Efren Delos Santos, Christoph Dehnhardt, Inder Chaudhary, Judy Lucas, Larry R. Feldberg, Robert Mallon
Purpose: The aim of this study was to show preclinical efficacy and clinical development potential of PKI-587, a dual phosphoinositide 3-kinase (PI3K)/mTOR inhibitor.Experimental Design: In vitro class 1 PI3K enzyme and human tumor cell growth inhibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66371ba1c25913d233d6894b0d41e8b5
https://doi.org/10.1158/1078-0432.c.6518286.v1
https://doi.org/10.1158/1078-0432.c.6518286.v1
Autor:
Irwin Hollander, Aranapakam Venkatesan, Semiramis Ayral-Kaloustian, Osvaldo dos Santos, Zecheng Chen, Efren Delos Santos, Christoph Dehnhardt, Inder Chaudhary, Judy Lucas, Larry R. Feldberg, Robert Mallon
Supplementary Figures S1-S10; Supplementary Tables S1-S5.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ed5c97961b902ade92d28cf1ef4eddb
https://doi.org/10.1158/1078-0432.22441143
https://doi.org/10.1158/1078-0432.22441143
Autor:
J P, Johnson, Thilo, Focken, Kuldip, Khakh, Parisa Karimi, Tari, Celine, Dube, Samuel J, Goodchild, Jean-Christophe, Andrez, Girish, Bankar, David, Bogucki, Kristen, Burford, Elaine, Chang, Sultan, Chowdhury, Richard, Dean, Gina, de Boer, Shannon, Decker, Christoph, Dehnhardt, Mandy, Feng, Wei, Gong, Michael, Grimwood, Abid, Hasan, Angela, Hussainkhel, Qi, Jia, Stephanie, Lee, Jenny, Li, Sophia, Lin, Andrea, Lindgren, Verner, Lofstrand, Janette, Mezeyova, Rostam, Namdari, Karen, Nelkenbrecher, Noah Gregory, Shuart, Luis, Sojo, Shaoyi, Sun, Matthew, Taron, Matthew, Waldbrook, Diana, Weeratunge, Steven, Wesolowski, Aaron, Williams, Michael, Wilson, Zhiwei, Xie, Rhena, Yoo, Clint, Young, Alla, Zenova, Wei, Zhang, Alison J, Cutts, Robin P, Sherrington, Simon N, Pimstone, Raymond, Winquist, Charles J, Cohen, James R, Empfield
Publikováno v:
eLife. 11
NBI-921352 (formerly XEN901) is a novel sodium channel inhibitor designed to specifically target Na
Publikováno v:
Journal of the American Chemical Society. 121:10848-10849
Chiral methyl groups in the form of chiral acetic acid (R)and (S)-1 have been invaluable for the elucidation of numerous biochemical mechanisms.1 So far, two basically different approaches to (R)and (S)-1 have been reported: The first one (Arigoni st